首页|原发性喉癌血清COX-2 PTTG1 TLR4水平与临床病理特征及预后生存状况的关系探讨

原发性喉癌血清COX-2 PTTG1 TLR4水平与临床病理特征及预后生存状况的关系探讨

扫码查看
目的:探究原发性喉癌血清环氧合酶-2(COX-2)、垂体瘤转化基因1(PTTG1)、Toll样受体4(TLR4)水平与临床病理特征及预后生存状况的关系。方法:选取 2021 年 5 月至 2023 年 3 月四川省达州市中心医院105 例原发性喉癌患者、105 例喉部良性病变患者分别作为观察组和对照组。比较两组血清COX-2、PTTG1、TLR4 水平,多元线性回归分析血清COX-2、PTTG1、TLR4 水平与临床病理特征的关系,随访3 年,比较不同血清COX-2、PTTG1、TLR4 水平患者预后生存率。结果:观察组COX-2、PTTG1、TLR4 水平分别为(38。89±12。14)ng/L、(140。17±30。25)pg/mL、(13。94±3。25)ng/mL均高于对照组(17。63±5。09)ng/L、(98。49±15。63)pg/mL、(8。72±2。13)ng/mL(t=16。549、12。543、13。765,P 均<0。05);多元线性回归分析显示,临床分期(偏回归系数:0。714、0。722、0。719)、肿瘤分化程度(偏回归系数:0。756、0。749、0。798)及淋巴结转移(偏回归系数:0。802、0。798、0。713)均为原发性喉癌患者血清COX-2、PTTG1、TLR4 水平的影响因素(P<0。05);COX-2 高水平亚组 3 年总生存率、总生存率分别为80。77%、71。15%,明显高于低水平亚组95。83%、87。50%(P<0。05);PTTG1 高水平亚组 3 年总生存率、总生存率分别为80。39%、68。63%,明显高于低水平亚组95。92%、89。80%(P<0。05);TLR4 高水平亚组3 年总生存率、总生存率分别为78。85%、71。15%,明显高于低水平亚组97。92%、87。50%(P<0。05)。结论:原发性喉癌患者血清COX-2、PTTG1、TLR4 水平均较高,且其高水平状态与临床分期、肿瘤分化程度及淋巴结转移有关,检测COX-2、PTTG1、TLR4 水平可在一定程度上反映患者预后生存情况。
Relationship between Serum COX-2 PTTG1 TLR4 Levels and Clinicopathological Features Prognosis and Survival of Primary Laryngeal Carcinoma
Objective:To investigate the relationship between serum cyclooxygenase-2(COX-2),pitu-itary tumor transforming gene 1(PTTG1),toll-like receptor 4(TLR4)levels and clinicopathological fea-tures,prognosis,and survival of primary laryngeal cancer.Methods:A total of 105 patients with primary la-ryngeal cancer and 105 patients with benign laryngeal lesions in Dazhou City Central Hospital of Sichuan Prov-ince from May 2021 to March 2023 were selected as observation and control groups,respectively.The serum COX-2,PTTG1 and TLR4 levels of the two groups were compared,and the relationship between serum COX-2,PTTG1 and TLR4 levels,and clinicopathological features was analyzed using multiple linear regression,and the prognostic survival rate of the patients with different serum COX-2,PTTG1,and TLR4 levels was compared in the follow-up of 3 years.Results:The levels of COX-2,PTTG1,and TLR4 in the observation group were(38.89±12.14)ng/L,(140.17±30.25)pg/mL,and(13.94±3.25)ng/mL,respectively,which were higher than those in the control group(17.63±5.09)ng/L,(98.49±15.63)pg/mL,and(8.72±2.13)ng/mL(t=16.549,12.543,13.765,all P<0.05).Multiple linear regression analysis showed that clinical stage(partial regression coefficient:0.714,0.722,0.719),tumor differentiation degree(partial re-gression coefficient:0.756,0.749,0.798),and lymph node metastasis(partial regression coefficient:0.802,0.798,0.713)were the influencing factors for the levels of serum COX-2,PTTG1,and TLR4 in pa-tients with primary laryngeal cancer(P<0.05).The 3-year overall survival rate and overall survival rate of the COX-2 high-level subgroup were 80.77%and 71.15%,respectively,which were significantly higher than those of the low-level subgroup 95.83%and 87.50%(P<0.05);the 3-year overall survival rate and o-verall survival rate of the PTTG1 high-level subgroup were 80.39%and 68.63%,respectively,which were significantly higher than those of the low-level subgroup 95.92%and 89.80%(P<0.05);3-year overall survival rate and overall survival rate of TLR4 high-level subgroup were 78.85%and 71.15%,respectively,which were significantly higher than those of 97.92%and 87.50%in the low-level subgroup(P<0.05).Conclusion:The levels of serum COX-2,PTTG1,and TLR4 are high in patients with primary laryngeal canc-er,and their high levels are related to clinical stage,tumor differentiation,and lymph node metastasis.Detec-tion of COX-2,PTTG1,and TLR4 levels can reflect the prognosis and survival of patients to a certain extent.

Primary laryngeal carcinomaPathological featuresPrognosis survivalCOX-2PTTG1TLR4

吴建、杨令、王东

展开 >

四川省达州市中心医院耳鼻喉科,四川 达州 635000

原发性喉癌 病理特征 预后生存 COX-2 PTTG1 TLR4

2021年四川省医学(青年创新)科研课题项目

S21525

2024

河北医学
河北省医学会

河北医学

CSTPCD
影响因子:1.915
ISSN:1006-6233
年,卷(期):2024.30(9)
  • 3